These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32443147)

  • 1. Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations.
    Jager NGL; van Hest RM; Xie J; Wong G; Ulldemolins M; Brüggemann RJM; Lipman J; Roberts JA
    J Antimicrob Chemother; 2020 Sep; 75(9):2641-2649. PubMed ID: 32443147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
    Ulldemolins M; Roberts JA; Wallis SC; Rello J; Lipman J
    J Antimicrob Chemother; 2010 Aug; 65(8):1771-8. PubMed ID: 20530507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High unbound flucloxacillin fraction in critically ill patients.
    Wallenburg E; Ter Heine R; de Lange DW; van Leeuwen H; Schouten JA; Ten Oever J; Kolwijck E; Burger DM; Pickkers P; Gieling EM; de Maat MM; Frenzel T; Brüggemann RJ
    J Antimicrob Chemother; 2021 Nov; 76(12):3220-3228. PubMed ID: 34463730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic modelling of total and unbound flucloxacillin in non-critically ill patients to devise a rational continuous dosing regimen.
    Wilkes S; van Berlo I; Ten Oever J; Jansman F; Ter Heine R
    Int J Antimicrob Agents; 2019 Mar; 53(3):310-317. PubMed ID: 30472288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target attainment and population pharmacokinetics of flucloxacillin in critically ill patients: a multicenter study.
    Meenks SD; Punt N; le Noble JLML; Foudraine NA; Neef K; Janssen PKC
    Crit Care; 2023 Mar; 27(1):82. PubMed ID: 36869388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose optimization of cefotaxime as pre-emptive treatment in critically ill adult patients: A population pharmacokinetic study.
    Roelofsen EE; Abdulla A; Muller AE; Endeman H; Gommers D; Dijkstra A; Hunfeld NGM; de Winter BCM; Koch BCP
    Br J Clin Pharmacol; 2023 Feb; 89(2):705-713. PubMed ID: 35942921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid.
    Drennan PG; Green JK; Gardiner SJ; Metcalf SCL; Kirkpatrick CMJ; Everts RJ; Zhang M; Chambers ST
    Br J Clin Pharmacol; 2021 Dec; 87(12):4681-4690. PubMed ID: 33963595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.
    Ulldemolins M; Roberts JA; Rello J; Paterson DL; Lipman J
    Clin Pharmacokinet; 2011 Feb; 50(2):99-110. PubMed ID: 21142293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients.
    Heffernan AJ; Sime FB; Kumta N; Wallis SC; McWhinney B; Ungerer J; Wong G; Joynt GM; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0218921. PubMed ID: 35575578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of flucloxacillin as intermittent bolus infusion in patients with Staphylococcus aureus bloodstream infection.
    Hermann L; Schöning V; Dräger S; Rentsch K; Moser S; Gürtler N; Sendi P; Osthoff M; Hammann F
    J Antimicrob Chemother; 2024 Aug; 79(8):2031-2039. PubMed ID: 38946285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.
    Landersdorfer CB; Kirkpatrick CM; Kinzig-Schippers M; Bulitta JB; Holzgrabe U; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3290-7. PubMed ID: 17576847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of protein binding of flucloxacillin in healthy volunteers and hospitalized patients.
    Wallenburg E; Brüggemann RJM; Roberts JA; Jager NGL; Ulldemolins M; Wilkes S; Schouten J; Chin PKL; Ter Heine R
    Clin Microbiol Infect; 2022 Mar; 28(3):446.e1-446.e7. PubMed ID: 34245903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probability of pharmacological target attainment with flucloxacillin in Staphylococcus aureus bloodstream infection: a prospective cohort study of unbound plasma and individual MICs.
    Moser S; Rehm S; Guertler N; Hinic V; Dräger S; Bassetti S; Rentsch KM; Sendi P; Osthoff M
    J Antimicrob Chemother; 2021 Jun; 76(7):1845-1854. PubMed ID: 33860325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic/pharmacodynamic target attainment of ceftriaxone 2 g once daily in non-critically ill hospitalized adult patients during the acute phase of infection.
    van den Broek AK; van Schip A; Visser CE; Bos JC; Prins JM; van Hest RM
    Br J Clin Pharmacol; 2023 Nov; 89(11):3262-3272. PubMed ID: 37309251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
    Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of unbound ceftriaxone in a critically ill population.
    Meenks SD; le Noble JLML; Foudraine NA; de Vries F; Neef K; Janssen PKC
    Int J Clin Pharmacol Ther; 2022 Sep; 60(9):373-383. PubMed ID: 35861497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.
    Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal Clearance.
    Béranger A; Benaboud S; Urien S; Moulin F; Bille E; Lesage F; Zheng Y; Genuini M; Gana I; Renolleau S; Hirt D; Tréluyer JM; Oualha M
    Clin Pharmacokinet; 2019 Feb; 58(2):223-233. PubMed ID: 29862466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.